Kim R. Tsuchimoto - 30 Sep 2021 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Financial Officer
Signature
/s/ Kim R. Tsuchimoto
Issuer symbol
MNPR
Transactions as of
30 Sep 2021
Net transactions value
-$2,060
Form type
4
Filing time
01 Oct 2021, 19:29:59 UTC
Previous filing
02 Jul 2021
Next filing
04 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Options Exercise +1,221 +46% 3,892 30 Sep 2021 Direct F1
transaction MNPR Common Stock Tax liability $2,060 -423 -11% $4.87 3,469 30 Sep 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Restricted Stock Units Options Exercise $0 -1,221 -7.1% $0.000000 15,873 30 Sep 2021 Common Stock 1,221 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired on vesting and settlement of restricted stock units.
F2 On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.